WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV

WIRB - 一项开放标签、多剂量、交叉研究来评估：HIV

• 批准号: 8167327
• 负责人: Steven L. Zeichner
• 金额: $ 0.31万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-20 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167327
• 关键词: 18 year old; Adherence; Child; Computer Retrieval of Information on Scientific Projects Database; Cross-Over Studies; Dose; Drug Formulations; Drug Kinetics; Funding; Grant; HIV; Institution; Marketing; Nevirapine; Oral; Regimen; Relative (related person); Research; Research Personnel; Resources; Source; Suspension substance; Suspensions; Tablets; Therapeutic; United States National Institutes of Health; Viral; antiretroviral therapy; compliance behavior; improved; open label; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to establish the pharmacokinetic profile at steady state of nevirapine XR in children from e3 to 18 years of age. Adherence is a major factor in determining the degree of viral suppression achieved in response to antiretroviral therapy. An extended release formulation of nevirapine may offer a meaningful therapeutic benefit, relative to marketed nevirapine oral suspension and 200 mg BID tablets by facilitating a once daily dosing regimen, thus improving treatment compliance. In addition, nevirapine extended release could demonstrate improved tolerability in comparison with the marketed suspension.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目的是建立奈韦拉平XR的稳态药动学曲线 在E3至18岁的儿童中。依从性是决定 对抗逆转录病毒治疗的反应实现了病毒抑制。一个扩展版本 与市场上销售的药物相比，奈韦拉平的配方可能提供有意义的治疗益处 奈韦拉平口服混悬液和200 mg Bid片剂， 从而提高治疗依从性。此外，奈韦拉平缓释剂可能 证明与市场上销售的悬浮液相比，耐受性更好。